Multiple vaccines and therapeutic options will be needed to end this pandemic
In the opening weeks of 2021, as vaccines began their slow march across populations, two pharmaceutical companies turned their attention to what comes after infection — the question of treatment. Vir Biotechnology and GlaxoSmithKline, partnering with the UK's adaptive AGILE research network, began the first human trials of VIR-7832, an antibody designed not merely to neutralize the coronavirus but to sharpen the immune system's own memory against it. The move reflected a growing recognition that no single tool — however promising — could answer the full complexity of a pandemic.
- Even as vaccine rollouts accelerated, hospitalization rates remained high enough to expose a critical gap: the world still lacked proven treatments for those already infected.
- VIR-7832 entered human trials carrying an unusual dual promise — clearing infected cells while also amplifying the T-cell response, a mechanism no approved therapy had yet combined.
- The AGILE platform injected urgency into the process itself, using adaptive protocols that allowed multiple treatments to be evaluated simultaneously rather than queued in sequence.
- A sprawling coalition of British universities, hospital trusts, and research facilities mobilized to enroll patients, turning the trial into a coordinated national effort rather than a single-site experiment.
- With the companion antibody VIR-7831 already in Phase 3 testing, the companies were running a portfolio strategy — placing parallel bets in hopes that science, moving fast enough, might outpace the virus.
In January 2021, Vir Biotechnology and GlaxoSmithKline announced they would begin the first human trials of VIR-7832, a new COVID-19 antibody, in partnership with AGILE — a UK research initiative built for exactly this kind of rapid-response science. The trial, targeting patients with mild to moderate infection, was set to open in the first quarter of the year.
What made VIR-7832 distinctive was its dual mechanism. Preclinical work suggested it could both help the body clear coronavirus-infected cells and strengthen the virus-specific T-cell response — offering a therapeutic angle that differed meaningfully from the vaccines already in circulation. The hope was that, given early enough, it might blunt the disease before it turned severe.
The AGILE platform was itself a kind of innovation — a network spanning the University of Liverpool, Liverpool School of Tropical Medicine, the University of Southampton, Lancaster University, and multiple NHS trusts, all operating under flexible, adaptive trial protocols that allowed researchers to test several candidates in parallel and adjust based on emerging data.
GSK's chief scientific officer Hal Barron was candid about the reasoning: vaccines had achieved something remarkable, but infection and hospitalization rates made clear that treatment options remained urgently necessary. VIR-7832 was not the partnership's only bet — its predecessor, VIR-7831, was already deep into two Phase 3 trials. The two antibodies running in tandem signaled a deliberate portfolio strategy, a recognition that in a pandemic, the cost of narrowing too soon is measured in lives.
Two pharmaceutical companies announced in January 2021 that they would begin testing a new COVID-19 antibody in British patients, marking the first time the experimental drug would be tried in humans. Vir Biotechnology and GlaxoSmithKline had partnered with AGILE, a U.K.-based research initiative, to launch a Phase 1b/2a clinical trial of VIR-7832 in people with mild to moderate COVID-19 infection. The trial was scheduled to open in the first quarter of that year.
VIR-7832 is a neutralizing antibody designed to work in two ways. Preclinical research suggested it could enhance the body's ability to clear cells infected with the coronavirus, and it might also strengthen the immune system's virus-specific T-cell response—potentially helping both treat and prevent COVID-19. This dual mechanism set it apart from other therapeutic approaches being pursued at the time, offering a different angle of attack than the vaccines that were already rolling out across the world.
The AGILE platform itself represented an innovation in how clinical trials could be conducted during a pandemic. The initiative, coordinated by the National Institute for Health Research Southampton Clinical Trials Unit and spanning multiple universities and hospital trusts across the U.K., was built to move quickly. It used flexible protocols and adaptive statistical models that allowed researchers to evaluate multiple candidate treatments in parallel, rather than running separate trials for each drug. This structure meant the system could respond to emerging data and adjust course without losing momentum.
The collaboration brought together the University of Liverpool, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, the University of Southampton, and Lancaster University. The network of U.K. Clinical Research Facilities provided the infrastructure to enroll and monitor patients across the country.
Hal Barron, the chief scientific officer and head of research and development at GSK, framed the partnership as essential to the broader pandemic response. He acknowledged that vaccines had been a major success, yet infection and hospitalization rates remained high enough to justify developing multiple treatment options. The company expected the AGILE trial to yield insights into how VIR-7832 might work when given early in the course of infection, before the disease had progressed to severe stages.
This was not the first antibody the Vir-GSK collaboration had moved into testing. VIR-7831, an earlier candidate from the same partnership, was already in two Phase 3 trials—one focused on high-risk patients who might otherwise be hospitalized, and another on people already hospitalized with COVID-19. The fact that VIR-7832 was entering human trials while its predecessor was still in late-stage testing suggested the companies were pursuing a portfolio approach, hedging their bets across multiple candidates in hopes that at least one would prove effective and safe enough to reach patients.
Notable Quotes
While vaccine development has been very successful, current infection and hospitalization rates show that multiple vaccines and therapeutic options will be needed to combat and ultimately end this pandemic.— Hal Barron, Chief Scientific Officer and President of R&D, GSK
The Hearth Conversation Another angle on the story
Why does it matter that this is the first time VIR-7832 is being tested in humans? Doesn't that happen with every new drug?
It does, but the timing and the context matter here. This is January 2021, mid-pandemic. They're not waiting years to move from lab to clinic—they're moving fast because people are dying. And they're testing it through AGILE, which is designed to learn quickly.
So AGILE is just a faster trial system?
It's more than that. It's adaptive. Instead of locking in a protocol at the start and running it for two years, AGILE can adjust as data comes in. It can test multiple drugs at once. It's built for pandemic speed.
The antibody does two things—clear infected cells and boost T-cells. Why is that combination important?
Because vaccines teach your immune system to recognize the virus, but antibodies are like sending in reinforcements immediately. If you give them early, when someone first gets sick, you're hitting the virus from two angles at once. You're not just blocking it; you're also making sure your body's own immune cells can finish the job.
They already have another antibody in Phase 3 trials. Why launch a second one?
Because you don't know which one will work. Maybe one is better for early treatment, another for hospitalized patients. Maybe one has side effects the other doesn't. You run them in parallel and see what the data tells you. It's insurance.
What happens if both work?
Then you have options. You can use them in different situations, or combine them. But first you have to know if either one works at all.